Creating nanobodies to target harmful tau proteins in Alzheimer's disease
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease
This study is looking at new tiny proteins called nanobodies that could help stop the harmful tau proteins linked to Alzheimer's disease, with the hope of finding better treatments for people living with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Puget Sound Healthcare System NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11098435 on NIH RePORTER |
What this research studies
This research focuses on developing nanobodies that can specifically target and inhibit the harmful tau proteins associated with Alzheimer's disease and related dementias. By understanding how MSUT2 influences tau toxicity in the brain, the researchers aim to create biologic agents that can potentially reverse the damage caused by tau pathology. The study involves using advanced techniques to design and test these nanobodies in preclinical models, which may lead to new therapeutic options for patients suffering from Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias who exhibit symptoms linked to tau pathology.
Not a fit: Patients with other forms of dementia that do not involve tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that modify the disease process of Alzheimer's disease rather than just alleviating symptoms.
How similar studies have performed: While targeting tau proteins is a relatively novel approach, preliminary studies have shown promise in similar strategies, indicating potential for success.
Where this research is happening
Seattle, United States
- VA Puget Sound Healthcare System — Seattle, United States (Active)
Researchers
- Principal investigator: Kraemer, Brian C. — VA Puget Sound Healthcare System
- Study coordinator: Kraemer, Brian C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.